Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGKA | P23743 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 2/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 3/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | PAM | P19021 | 2/20 | 0.52 |
| ▸ | CES2 | O00748 | 3/20 | 0.50 |
| ▸ | CES1 | P23141 | 3/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.48 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.48 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.48 |
| ▸ | PPARG | P37231 | 1/20 | 0.48 |
| ▸ | PPARD | Q03181 | 1/20 | 0.48 |
| ▸ | PPARA | Q07869 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2116875 | 1.00 | DGKA (0.57) | DGKAMAPTMAPK1LMNAALDH1A1 | |
| SCHEMBL6561403 | 1.00 | DGKA (0.57) | DGKAMAPTMAPK1LMNAALDH1A1 | |
| SCHEMBL6561773 | 1.00 | DGKA (0.57) | DGKAMAPTMAPK1LMNAALDH1A1 | |
| SCHEMBL6561136 | 1.00 | DGKA (0.57) | DGKAMAPTMAPK1LMNAALDH1A1 | |
| SCHEMBL9295670 | 1.00 | DGKA (0.57) | DGKAMAPTMAPK1LMNAALDH1A1 | |
| SCHEMBL3172247 | 1.00 | DGKA (0.57) | DGKAMAPTMAPK1LMNAALDH1A1 | |
| SCHEMBL11047570 | 1.00 | DGKA (0.57) | DGKAMAPTMAPK1LMNAALDH1A1 | |
| SCHEMBL4449355 | 0.98 | DGKA (0.55) | DGKAMAPTMAPK1LMNAALDH1A1 | |
| SCHEMBL31202856 | 0.98 | DGKA (0.55) | DGKAMAPTMAPK1LMNAALDH1A1 | |
| SCHEMBL28663735 | 0.98 | DGKA (0.55) | DGKAMAPTMAPK1LMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1547474-A | Skin-permeable selective cyclooxygenase-2 inhibitor composition | — | 2004-11-17 | — | — | CN | claimed |
| EP-1404345-A2 | SKIN-PERMEABLE SELECTIVE CYCLOOXYGENASE-2 INHIBITOR COMPOSITION | Pharmacia Corporation (US) | 2004-04-07 | — | — | EP | claimed |
| US-20030161867-A1 | Skin-permeable selective cyclooxygenase-2 inhibitor composition | PHARMACIA CORPORATION | 2003-08-28 | — | — | US | claimed |
| WO-2002096435-A2 | SKIN-PERMEABLE COMPOSITION COMPRISING A SELECTIVE CYCLOOXYGENASE-2 INHIBITOR A MONOHYDRIC ALCOHOL | PHARMACIA CORPORATION (US) | 2002-12-05 | — | — | WO | claimed |
| US-5912009-A | TRANSDERMAL DRUG DELIVERY | THERATECH, INC. (US) | 1999-06-15 | — | — | US | claimed |
| US-20250099436-A1 | DRUG FOR TREATING TINNITUS | UNIV SOUTH FLORIDA (US) | 2025-03-27 | — | — | US | disclosed |
| US-12194026-B2 | Drug for treating tinnitus | UNIVERSITY OF SOUTH FLORIDA (US) | 2025-01-14 | — | — | US | disclosed |
| EP-3870159-B1 | DRUG FOR TREATING TINNITUS | UNIV SOUTH FLORIDA (US) | 2024-11-13 | — | — | EP | disclosed |
| US-20210393596-A1 | DRUG FOR TREATING TINNITUS | SCOTT, LUISA LYNN | 2021-12-23 | — | — | US | disclosed |
| EP-2726080-A1 | ALCAFTADINE FOR USE IN THE TREATMENT OF URTICARIA | Allergan, Inc. (US) | 2014-05-07 | — | — | EP | disclosed |
| CN-103764150-A | Application of alcaftadine in treating urticaria | ALLERGAN INC | 2014-04-30 | — | — | CN | disclosed |
| WO-2013003825-A1 | ALCAFTADINE FOR USE IN THE TREATMENT OF URTICARIA | ALLERGAN, INC. (US) | 2013-01-03 | — | — | WO | disclosed |
| WO-2001032115-A1 | TRANSDERMAL ADMINISTRATION OF HUPERZINE | XEL HERBACEUTICALS (US) | 2001-05-10 | — | — | WO | disclosed |
| EP-0971662-A1 | FATTY ACID ESTERS OF GLYCOLIC ACID AND ITS SALTS AS PERMEATION ENHANCERS | TheraTech, Inc. (US) | 2000-01-19 | — | — | EP | disclosed |
| CN-1231592-A | Fatty acid esters of glycolic and its salts as permeation enhancers | THERATECH INC (US) | 1999-10-13 | — | — | CN | disclosed |
| US-5912009-A | TRANSDERMAL DRUG DELIVERY | THERATECH, INC. (US) | 1999-06-15 | — | — | US | disclosed |
| WO-1998018416-A1 | FATTY ACID ESTERS OF GLYCOLIC ACID AND ITS SALTS AS PERMEATION ENHANCERS | THERATECH, INC. (US) | 1998-05-07 | — | — | WO | disclosed |
| EP-0224796-B1 | DETERGENT COMPOSITION | Kao Corporation (JP) | 1991-10-16 | — | — | EP | disclosed |
| US-4758376-A | Phosphate surfactant based detergent compositions | KAO CORPORATION (JP) | 1988-07-19 | — | — | US | disclosed |
| EP-0224796-A2 | Detergent composition | Kao Corporation (JP) | 1987-06-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210393596-A1 | DRUG FOR TREATING TINNITUS | CHAT, SLC18A2, TRPV1 | DGKA 2013/4885MAPT 803/4885MAPK1 2851/4885 |
| US-20250099436-A1 | DRUG FOR TREATING TINNITUS | CHAT, SLC18A2, TRPV1 | DGKA 2013/4885MAPT 803/4885MAPK1 2851/4885 |
| US-20030161867-A1 | Skin-permeable selective cyclooxygenase-2 inhibitor composition | PTGS2, PTGES2, PTGER2 | DGKA 452/4885MAPT 1428/4885MAPK1 1120/4885 |
| US-12194026-B2 | Drug for treating tinnitus | CHAT, SLC18A2, TRPV1 | DGKA 2013/4885MAPT 803/4885MAPK1 2851/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.